A Phase 4 interventional study of B/F/TAF in HIV-1-infection, sponsored by Gilead Sciences. Completed at 18 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.
Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical study is to learn how safe it is to switch to an oral therapy of Bictegravir/Emtricitabine/Tenofovir (B/F/TAF) from Cabotegravir + Rilpivirine (CAB+RPV) in participants living with virologically suppressed human immunodeficiency virus type 1 (HIV-1), meaning participants with HIV RNA levels below detectable levels.
The primary objective of this study is to assess the safety of switching to B/F/TAF in virologically suppressed participants unable/unwilling to continue on CAB+RPV intramuscular (IM) injections or wishing to switch to oral therapy through Week 12.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a fixed dose combination of B/F/TAF 50/200/25 mg once daily for 24 weeks.
Drug: B/F/TAF
Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide
Tablets administered orally without regard to food
Also known as: Biktarvy ®
Percentage of Participants Experiencing Treatment Emergent Grade 3 or 4 Drug-related Adverse Events Through Week 12 (Co-Primary Endpoint)
Treatment emergent adverse events (TEAEs) were defined as any AE that began on or after the date of first dose of study drug up to the date of last dose of study drug plus 30 days or any AE leading to study drug discontinuation. The severity of AEs were be graded using the Division of AIDS (DAIDS) Toxicity Grading Scale. The DAIDS grading table provide an adverse events (AE) severity grading scale ranging from grades 1 to 5 with descriptions for each AE based on the following general guidelines: * Grade 1 indicates a mild event * Grade 2 indicates a moderate event * Grade 3 indicates a severe event * Grade 4 indicates a potentially life-threatening event * Grade 5 indicates death
Time frame: Week 12
Percentage of Participants Experiencing Treatment-emergent Grade 3 or 4 Laboratory Abnormalities Through Week 12 (Co-Primary Endpoint)
Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any time after baseline up to and including the date of last dose of study drug plus 30 days. The DAIDS Toxicity Grading Scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that did not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening.
Time frame: Week 12
Plasma Concentrations of Cabotegravir (CAB), and Rilpivirine (RPV) at Day 1 (Predose)
Time frame: Day 1 (Predose)
Plasma Concentration of Bictegravir (BIC), CAB, and RPV at Week 4
Time frame: Week 4 (at trough and 2 hours postdose)
Plasma Concentration of BIC, CAB, and RPV at Week 12
Time frame: Week 12 (at trough and 2 hours postdose)
Plasma Concentration of BIC, CAB, and RPV at Week 24
Time frame: Week 24 (at trough and 2 hours postdose)
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 12 as Determined by Missing = Excluded Approach
This outcome measure analyzed using the Missing = Excluded (M = E) method. In this approach, all missing data were excluded in the analysis.
Time frame: Week 12
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by Missing = Excluded Approach
This outcome measure analyzed using the Missing = Excluded (M = E) method. In this approach, all missing data were excluded in the analysis.
Time frame: Week 24
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 12 as Determined by Discontinuation = Failure Approach
This outcome measure was analyzed using the Discontinuation = Failure (D = F) method. In this approach, all discontinuation were treated as HIV-1 RNA \>= 50 copies/mL (failure) in the analysis.
Time frame: Week 12
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by Discontinuation = Failure Approach
This outcome measure was analyzed using the Discontinuation = Failure (D = F) method. In this approach, all discontinuation were treated as HIV-1 RNA \>= 50 copies/mL (failure) in the analysis.
Time frame: Week 24
Percentage of Participants With Discontinuation of B/F/TAF by Week 12
Time frame: Up to 12 Weeks
Percentage of Participants With Discontinuation of B/F/TAF by Week 24
Time frame: Up to 24 Weeks
Percentage of Participants Experiencing Treatment-emergent Grade 3 or 4 Laboratory Abnormalities Through Week 24
Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any time after baseline up to and including the date of last dose of study drug plus 30 days. The DAIDS Toxicity Grading Scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that did not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening.
Time frame: Week 24
HIV Treatment Satisfaction (HIVTSQc) Score at Week 4
The HIVTSQc was a 1-12 items questionnaire. Each item was scored -3 to 3. The total score ranged from -33 to +33, based on 11 items. Higher the score, greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment. A score of 0 represented no change.
Time frame: Week 4
Participants were enrolled at study sites in the United States, France, and Canada.
| Milestone | Bictegravir/Emtricitabine/Tenofovir (B/F/TAF) |
|---|---|
| Started | 33 |
| Completed | 29 |
| Not completed | 4 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Death | 1 |
| Withdrew: Withdrew consent | 1 |
Treatment emergent adverse events (TEAEs) were defined as any AE that began on or after the date of first dose of study drug up to the date of last dose of study drug plus 30 days or any AE leading to study drug discontinuation. The severity of AEs were be graded using the Division of AIDS (DAIDS) Toxicity Grading Scale. The DAIDS grading table provide an adverse events (AE) severity grading scale ranging from grades 1 to 5 with descriptions for each AE based on the following general guidelines: * Grade 1 indicates a mild event * Grade 2 indicates a moderate event * Grade 3 indicates a severe event * Grade 4 indicates a potentially life-threatening event * Grade 5 indicates death
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants Experiencing Treatment Emergent Grade 3 or 4 Drug-related Adverse Events Through Week 12 (Co-Primary Endpoint) | 0 |
Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any time after baseline up to and including the date of last dose of study drug plus 30 days. The DAIDS Toxicity Grading Scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that did not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening.
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants Experiencing Treatment-emergent Grade 3 or 4 Laboratory Abnormalities Through Week 12 (Co-Primary Endpoint) | 3.1 |
| ng/mL | B/F/TAF |
|---|---|
| CAB | 1650 ± 1010 |
| RPV | 68.3 ± 26.1 |
| ng/mL | B/F/TAF |
|---|---|
| BIC, Trough | 3590 ± 2030 |
| BIC, 2 Hours Postdose | 6350 ± 2210 |
| CAB, Trough | 929 ± 739 |
| CAB, 2 Hours Postdose | 975 ± 761 |
| RPV, Trough | 57.8 ± 20.8 |
| RPV, 2 Hours Postdose | 55.7 ± 21.1 |
| ng/mL | B/F/TAF |
|---|---|
| BIC, Trough | 3850 ± 2550 |
| BIC, 2 Hours Postdose | 6550 ± 2100 |
| CAB, Trough | 667 ± 982 |
| CAB, 2 Hours Postdose | 647 ± 873 |
| RPV, Trough | 47.2 ± 22.4 |
| RPV, 2 Hours Postdose | 45.4 ± 22.4 |
| ng/mL | B/F/TAF |
|---|---|
| BIC, Trough | 2820 ± 1530 |
| BIC, 2 Hours Postdose | 6410 ± 1340 |
| CAB, Trough | NA ± NA |
| CAB, 2 Hours Postdose | NA ± NA |
| RPV, Trough | 37.1 ± 22.3 |
| RPV, 2 Hours Postdose | 33.1 ± 17.4 |
This outcome measure analyzed using the Missing = Excluded (M = E) method. In this approach, all missing data were excluded in the analysis.
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 12 as Determined by Missing = Excluded Approach | 0.0 (0.0 to 11.6) |
This outcome measure analyzed using the Missing = Excluded (M = E) method. In this approach, all missing data were excluded in the analysis.
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by Missing = Excluded Approach | 0.0 (0.0 to 11.9) |
This outcome measure was analyzed using the Discontinuation = Failure (D = F) method. In this approach, all discontinuation were treated as HIV-1 RNA \>= 50 copies/mL (failure) in the analysis.
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 12 as Determined by Discontinuation = Failure Approach | 3.2 (0.1 to 16.7) |
This outcome measure was analyzed using the Discontinuation = Failure (D = F) method. In this approach, all discontinuation were treated as HIV-1 RNA \>= 50 copies/mL (failure) in the analysis.
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Determined by Discontinuation = Failure Approach | 9.4 (2.0 to 25.0) |
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants With Discontinuation of B/F/TAF by Week 12 | 3.0 (0.1 to 15.8) |
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants With Discontinuation of B/F/TAF by Week 24 | 9.1 (1.9 to 24.3) |
Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any time after baseline up to and including the date of last dose of study drug plus 30 days. The DAIDS Toxicity Grading Scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that did not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening.
| percentage of participants | B/F/TAF |
|---|---|
| Percentage of Participants Experiencing Treatment-emergent Grade 3 or 4 Laboratory Abnormalities Through Week 24 | 6.3 |
The HIVTSQc was a 1-12 items questionnaire. Each item was scored -3 to 3. The total score ranged from -33 to +33, based on 11 items. Higher the score, greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment. A score of 0 represented no change.
| score on scale | B/F/TAF |
|---|---|
| HIV Treatment Satisfaction (HIVTSQc) Score at Week 4 | 27 ± 9.0 |
Collected over All-cause mortality: Up to 25 weeks; Adverse events: Up to 24 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| B/F/TAF | 1/33 (3%) | 2/33 (6.1%) | 10/33 (30.3%) |
| Event | B/F/TAF |
|---|---|
| Abdominal pain upperGastrointestinal disorders | 1/33 |
| Diverticulum intestinalGastrointestinal disorders | 1/33 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/33 |
| Road traffic accidentInjury, poisoning and procedural complications | 1/33 |
| Event | B/F/TAF |
|---|---|
| DiarrhoeaGastrointestinal disorders | 4/33 |
| NauseaGastrointestinal disorders | 2/33 |
| VomitingGastrointestinal disorders | 2/33 |
| Upper respiratory tract infectionInfections and infestations | 2/33 |
| Back painMusculoskeletal and connective tissue disorders | 2/33 |
| Neck painMusculoskeletal and connective tissue disorders | 2/33 |
| DizzinessNervous system disorders | 2/33 |
| HeadacheNervous system disorders | 2/33 |
The Safety Analysis Set included all enrolled participants who have received at least 1 dose of the study drug (B/F/TAF).
| Age, Categorical(Participants) | B/F/TAF |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 28 |
| >=65 years | 5 |
| Age, Continuous(years) | B/F/TAF |
|---|---|
| Mean | 47 ± 14.7 |
| Sex: Female, Male(Participants) | B/F/TAF |
|---|---|
| Female | 9 |
| Male | 24 |
| Race/Ethnicity, Customized(Participants) | B/F/TAF |
|---|---|
| Race — White | 18 |
| Race — Black or African American | 6 |
| Race — Not Collected | 4 |
| Race — Other or More Than One Race | 2 |
| Race — American Indian or Alaska Native | 1 |
| Race — Asian | 1 |
| Race — Native Hawaiian or Other Pacific Islander | 1 |
| Race/Ethnicity, Customized(Participants) | B/F/TAF |
|---|---|
| Ethnicity — Not Hispanic or Latino | 20 |
| Ethnicity — Hispanic or Latino | 11 |
| Ethnicity — Not Collected | 2 |
| Region of Enrollment(Participants) | B/F/TAF |
|---|---|
| United States | 27 |
| France | 4 |
| Canada | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gileadclinicaltrials.com
Ran from Dec 2023 to primary completion in Jan 2025, 13 months.
Results were first posted in Feb 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide